Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9480	Companies
185535	Keywords
117927	Articles
99378	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 12/06/2023 at 14:30, 1 year 11 months ago

Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Napo Pharmaceuticals and Advocates for Collaborative Education (ACE) have released the abstract for a quality of life survey for individuals with a cancer diagnosis, shedding light on the challenges faced. The survey findings will be presented at the December 2023 SABCS, focusing on the impacts of cancer diagnosis and treatment on quality of life, including physical and emotional well-being, treatment side effects, and the consequences of managing those side effects

Napo Pharmaceuticals Advocates For Collaborative Education Cancer Survey Quality Of Life SABCS 2023
PRESS RELEASE

published on 12/04/2023 at 14:30, 2 years ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) has announced the renewal of conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) by the U.S. FDA for the treatment of chemotherapy-induced diarrhea (CID) in dogs. The renewal extends the validity until December 21, 2024, as the company plans a clinical field study to support full approval

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea
PRESS RELEASE

published on 11/30/2023 at 14:30, 2 years ago

Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
Jaguar Health, Inc. to present on Dec 5, 2023, at the MedInvest Oncology Investor Conference, discussing pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy

Crofelemer Jaguar Health Oncology Investor Conference Phase 3 Clinical Trial Cancer Therapy
PRESS RELEASE

published on 11/21/2023 at 14:30, 2 years ago

Top Line Data for Jaguar Health’s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
PRESS RELEASE

published on 11/14/2023 at 14:00, 2 years ago

Jaguar Health Reports Third Quarter 2023 Financial Results
PRESS RELEASE

published on 11/10/2023 at 22:15, 2 years ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRESS RELEASE

published on 11/09/2023 at 14:30, 2 years ago

Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
PRESS RELEASE

published on 11/08/2023 at 16:25, 2 years ago

Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
PRESS RELEASE

published on 11/08/2023 at 14:30, 2 years ago

Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
PRESS RELEASE

published on 11/07/2023 at 14:30, 2 years ago

REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST

Accesswire

Published on 12/05/2025 at 19:50, 2 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 32 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 7 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 32 minutes ago

NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 1 hour 52 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 53 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 1 hour 25 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 1 hour 36 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 2 hours ago

Issue of Equity
Published on 12/05/2025 at 17:46, 2 hours 5 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 2 hours 34 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 4 hours 41 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 11 hours 7 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day 1 hour ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day 2 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE